Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569591 · ClinicalTrials.gov registry record · NA
DDAVP for Pituitary Adenoma
A NA study of Pituitary Adenoma and Cushing's Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Recruiting
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04569591 is a NA study of Pituitary Adenoma and Cushing's Disease that is actively recruiting participants, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 22 participants, below the 286-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04569591, a NA study of Pituitary Adenoma and Cushing's Disease, is actively recruiting participants, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituitary adenomas in patients with Cushing s disease. Patients who have MRI-negative pituitary microadenomas will undergo FDG PET-imaging with DDAVP stimulation. Intravenous FDG will be given approximately four hours following DDAVP administration. Within 12 weeks after completion of the FDG high-resolution PET scan, patients will undergo surgical resection of the pituitary adenoma. Surgical and histological confirmation of adenoma location will be noted. All images will be read independently by neuroradiologists blinded to clinical and histopathological outcomes. The diagnostic and localization accuracy of PET-imaging will be assessed by comparing the PET findings with histopathology.
Conditions Studied
Interventions
- DRUG Desmopressin acetate
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2028-02-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04569591
The ClinicalTrials.gov registry entry for NCT04569591 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (92% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pituitary Adenoma appearing as the primary indexed condition, and to 1 intervention - of which Desmopressin acetate is the first listed.
NCT04569591 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04569591 about?
NCT04569591 is a clinical study titled "DDAVP for Pituitary Adenoma". This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituita...
What is the current status of trial NCT04569591?
This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2026-03-09. Estimated completion is 2028-02-26.
What conditions does trial NCT04569591 study?
This clinical trial studies the following conditions: Pituitary Adenoma, Cushing's Disease.
What interventions are being tested in trial NCT04569591?
The interventions under investigation include: Desmopressin acetate (DRUG).
Who is sponsoring clinical trial NCT04569591?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04569591 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
RECRUITING · Phase 4
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
RECRUITING · Phase 1
-
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Surgical Debulking of Pituitary Adenomas
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.